{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T01:50:21Z","timestamp":1781229021368,"version":"3.54.1"},"reference-count":122,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.clinthera.2021.12.005","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T15:57:49Z","timestamp":1646150269000},"page":"331-348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7658-9013","authenticated-orcid":false,"given":"Bushra Hassan","family":"Marouf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohaib","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal Basheer","family":"Mohamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3733-8331","authenticated-orcid":false,"given":"Bilal","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Schofield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akheel","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Kilpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Stefanutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Handrean","family":"Soran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.12.005_bib0001","series-title":"Hyperlipidaemia 3 Ed: Diagnosis and Management","author":"Durrington","year":"2007"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2018.72238","article-title":"Hypercholesterolaemia\u2014practical information for non-specialists","volume":"14","author":"Soran","year":"2018","journal-title":"Archives of medical science"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0003","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"European heart journal"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0004","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/MOL.0000000000000097","article-title":"The importance of considering LDL cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapy","volume":"25","author":"Soran","year":"2014","journal-title":"Current opinion in lipidology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0005","first-page":"2975","article-title":"Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment","volume":"36","author":"Soran","year":"2015","journal-title":"European heart journal"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0006","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/2047487316667785","article-title":"Are recent statin recommendations to employ fixed doses and abandon targets effective for treatment of hypercholesterolaemia? Investigation based on number needed to treat","volume":"24","author":"Soran","year":"2020","journal-title":"European journal of preventive cardiology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0007","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2018.08.040","article-title":"Optimising treatment of hyperlipidaemia: quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk","volume":"278","author":"Soran","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0008","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1161\/CIRCULATIONAHA.116.022146","article-title":"Cholesterol levels should play a more important role in identifying statin recipients","volume":"135","author":"Durrington","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0009","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/CIRCRESAHA.115.307611","article-title":"Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease","volume":"118","author":"Herrington","year":"2016","journal-title":"Circulation research"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0010","unstructured":"British Heart Foundation. UK Fact Sheet. in: 2021."},{"key":"10.1016\/j.clinthera.2021.12.005_bib0011","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1161\/01.CIR.100.10.1134","article-title":"Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association","volume":"100","author":"Grundy","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0012","series-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","first-page":"1670","volume":"376","author":"Baigent","year":"2010"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0013","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jama.1997.03550040069040","article-title":"Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials","volume":"278","author":"Hebert","year":"1997","journal-title":"The Journal of the American Medical Association"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0014","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1056\/NEJMc1509363","article-title":"Ezetimibe plus a statin after acute coronary syndromes","volume":"373","author":"Silbernagel","year":"2015","journal-title":"New England journal of medicine"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0015","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"New England journal of medicine"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0016","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/MOL.0000000000000433","article-title":"Evidence for more intensive cholesterol lowering","volume":"28","author":"Soran","year":"2017","journal-title":"Current opinion in lipidology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0017","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011581","article-title":"Association of lowering low-density lipoprotein cholesterol with contemporary lipid-lowering therapies and risk of diabetes mellitus: a systematic review and meta-analysis","volume":"8","author":"Khan","year":"2019","journal-title":"Journal of the American Heart Association"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0018","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"The Lancet"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0019","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.metabol.2014.02.014","article-title":"Statin treatment and new-onset diabetes: a review of proposed mechanisms","volume":"63","author":"Brault","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0020","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"The Lancet"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0021","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.jacl.2014.02.012","article-title":"An assessment by the Statin Diabetes Safety Task Force: 2014 update","volume":"8","author":"Maki","year":"2014","journal-title":"Journal of clinical lipidology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0022","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","article-title":"HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials","volume":"385","author":"Swerdlow","year":"2015","journal-title":"The Lancet"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0023","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1007\/s00125-010-1691-2","article-title":"Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice","volume":"53","author":"Kruit","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0024","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11892-009-0090-x","article-title":"Cholesterol in \u03b2-cell dysfunction: the emerging connection between HDL cholesterol and type 2 diabetes","volume":"10","author":"Brunham","year":"2010","journal-title":"Current diabetes reports"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0025","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nm1546","article-title":"\u03b2-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment","volume":"13","author":"Brunham","year":"2007","journal-title":"Nature medicine"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0026","first-page":"390","article-title":"Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials","volume":"6","author":"Naci","year":"2013","journal-title":"Circulation: cardiovascular quality and outcomes"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0027","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00001648-200109000-00017","article-title":"Lipid-lowering drugs and risk of myopathy: a population-based follow-up study","volume":"12","author":"Gaist","year":"2001","journal-title":"Epidemiology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0028","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.atherosclerosis.2020.06.023","article-title":"Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance","volume":"306","author":"Soran","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0029","first-page":"1","article-title":"Efficacy and safety of PCSK9 monoclonal antibodies","author":"Iqbal","year":"2019","journal-title":"Expert opinion on drug safety"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0030","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"New England journal of medicine"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0031","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"New England journal of medicine"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0032","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"New England journal of medicine"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0033","doi-asserted-by":"crossref","first-page":"422","DOI":"10.18433\/jpps31197","article-title":"Cardiovascular and safety events of PCSK9 inhibitors in statin-treated patients with cardiovascular risk: a systematic review and meta-analysis","volume":"23","author":"Zhao","year":"2020","journal-title":"Journal of pharmacy & pharmaceutical sciences: a publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne des Sciences Pharmaceutiques"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0034","unstructured":"Patni N, Ahmad Z, Wilson DP. Genetics and Dyslipidemia. [Updated 2020 Feb 11]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK395584\/."},{"key":"10.1016\/j.clinthera.2021.12.005_bib0035","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0022-2275(20)33515-X","article-title":"Evidence for a third genetic locus causing familial hypercholesterolemia: a non-LDLR, non-APOB kindred","volume":"40","author":"Haddad","year":"1999","journal-title":"Journal of lipid research"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0036","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1086\/302370","article-title":"A third major locus for autosomal dominant hypercholesterolemia maps to 1p34. 1-p32","volume":"64","author":"Varret","year":"1999","journal-title":"The American journal of human genetics"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0037","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hipercolesterolemia","volume":"34","author":"Adifadel","year":"2003","journal-title":"Nature genetics"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0038","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0039","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1073\/pnas.0402133101","article-title":"Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype","volume":"101","author":"Maxwell","year":"2004","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0040","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1073\/pnas.0409736102","article-title":"Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment","volume":"102","author":"Maxwell","year":"2005","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0041","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nature genetics"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0042","doi-asserted-by":"crossref","first-page":"A1372","DOI":"10.1016\/S0735-1097(14)61372-3","article-title":"LDL cholesterol reduction with BMS-962476, an adnectin inhibitor of PCSK9: results of a single ascending dose study","volume":"63","author":"Stein","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0043","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/mt.2011.260","article-title":"PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates","volume":"20","author":"Lindholm","year":"2012","journal-title":"Molecular therapy"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0044","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.atherosclerosis.2014.05.931","article-title":"CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism","volume":"235","author":"Dong","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0045","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"New England journal of medicine"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0046","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/bcp.12738","article-title":"Antisense-mediated reduction of proprotein convertase subtilisin\/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial","volume":"80","author":"van Poelgeest","year":"2015","journal-title":"British journal of clinical pharmacology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0047","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.atherosclerosis.2019.06.019","article-title":"Safety, tolerability and LDL-C reduction with a novel anti-PCSK9 recombinant fusion protein (LIB003): results of a randomized, double-blind, placebo-controlled, phase 2 study","volume":"287","author":"Stein","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0048","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191895","article-title":"Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin\/kexin type 9 (PCSK9) epitope in mice","volume":"13","author":"Kawakami","year":"2018","journal-title":"PloS one"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-019-1457-8","article-title":"Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis","volume":"17","author":"Momtazi-Borojeni","year":"2019","journal-title":"BMC medicine"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2001882","article-title":"Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain","volume":"15","author":"Lintner","year":"2017","journal-title":"PLoS biology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0051","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1124\/jpet.117.246652","article-title":"Generation and characterization of a novel small biologic alternative to proprotein convertase subtilisin\/kexin type 9 (PCSK9) antibodies, DS-9001a, albumin binding domain\u2013fused anticalin protein","volume":"365","author":"Masuda","year":"2018","journal-title":"Journal of pharmacology and experimental therapeutics"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0052","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/eurheartj\/ehu095","article-title":"The Sirt1 activator SRT3025 provides atheroprotection in Apoe\u2212\/\u2212 mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression","volume":"36","author":"Miranda","year":"2015","journal-title":"European heart journal"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0053","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","year":"2017","journal-title":"New England journal of medicine"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0054","doi-asserted-by":"crossref","first-page":"E177","DOI":"10.1152\/ajpendo.00528.2014","article-title":"New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism","volume":"309","author":"Miyosawa","year":"2015","journal-title":"American journal of physiology-endocrinology and metabolism"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0055","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0056","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1161\/CIRCRESAHA.118.311227","article-title":"PCSK9: from basic science discoveries to clinical trials","volume":"122","author":"Shapiro","year":"2018","journal-title":"Circulation research"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0057","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11745-014-3895-6","article-title":"PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day","volume":"49","author":"Chen","year":"2014","journal-title":"Lipids"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0058","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s11255-017-1505-2","article-title":"PCSK9 in chronic kidney disease","volume":"49","author":"Pavlakou","year":"2017","journal-title":"International urology and nephrology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0059","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pharmtox-010716-104944","article-title":"PCSK9: regulation and target for drug development for dyslipidemia","volume":"57","author":"Burke","year":"2017","journal-title":"Annual review of pharmacology and toxicology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.abb.2017.06.001","article-title":"Hypercholesterolemia: the role of PCSK9","volume":"625","author":"Melendez","year":"2017","journal-title":"Archives of biochemistry and biophysics"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0061","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/0092-8674(83)90052-1","article-title":"Recycling receptors: the round-trip itinerary of migrant membrane proteins","volume":"32","author":"Brown","year":"1983","journal-title":"Cell"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0062","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.113.001592","article-title":"Serum proprotein convertase subtilisin\/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation","volume":"127","author":"Tavori","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0063","doi-asserted-by":"crossref","first-page":"28856","DOI":"10.1074\/jbc.M109.037085","article-title":"Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route","volume":"284","author":"Poirier","year":"2009","journal-title":"Journal of biological chemistry"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0064","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes","volume":"375","author":"Ference","year":"2016","journal-title":"New England journal of medicine"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0065","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"New England journal of medicine"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0066","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1161\/CIRCULATIONAHA.115.018531","article-title":"Circulating proprotein convertase subtilisin\/kexin type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors","volume":"133","author":"Leander","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0067","first-page":"94","article-title":"Proprotein convertase subtilisin\/kexin type 9, C-reactive protein, coronary severity, and outcomes in patients with stable coronary artery disease: a prospective observational cohort study","author":"Li","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0068","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-019-2123-9","article-title":"Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy","volume":"17","author":"Cao","year":"2019","journal-title":"Journal of translational medicine"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0069","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1161\/ATVBAHA.115.306172","article-title":"Association of proprotein convertase subtilisin\/kexin type 9 (PCSK9) with cardiovascular risk in primary prevention","volume":"35","author":"Zhu","year":"2015","journal-title":"Arteriosclerosis, thrombosis, and vascular biology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0070","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/dom.12788","article-title":"Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome","volume":"19","author":"Blom","year":"2017","journal-title":"Diabetes, obesity and metabolism"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0071","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0305-0491(71)90234-3","article-title":"The distribution and composition of serum lipoproteins in eighteen animals","volume":"40","author":"Mills","year":"1971","journal-title":"Comparative biochemistry and physiology part B: comparative biochemistry"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0072","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8598054","article-title":"Safety and efficacy of extremely low LDL-cholesterol levels and its prospects in hyperlipidemia management","author":"Bandyopadhyay","year":"2018","journal-title":"Journal of lipids"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0073","doi-asserted-by":"crossref","first-page":"e22919","DOI":"10.1002\/ajhb.22919","article-title":"Physical activity patterns and biomarkers of cardiovascular disease risk in hunter-gatherers","volume":"29","author":"Raichlen","year":"2017","journal-title":"American journal of human biology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0074","article-title":"PCSK9 loss-of-function variants, low-density lipoprotein cholesterol, and risk of coronary heart disease and stroke: data from 9 studies of blacks and whites","volume":"10","author":"Kent","year":"2017","journal-title":"Circulation: cardiovascular genetics"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0075","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.2174\/1381612824666181008110643","article-title":"Is very low LDL-C harmful?","volume":"24","author":"Faselis","year":"2018","journal-title":"Current pharmaceutical design"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0076","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Keech","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0077","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00392-016-1069-7","article-title":"Evidence-based goals in LDL-C reduction","volume":"106","author":"Soran","year":"2017","journal-title":"Clinical research in cardiology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0078","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0079","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11886-018-0995-6","article-title":"The association of statin therapy with incident diabetes: evidence, mechanisms, and recommendations","volume":"20","author":"Agarwala","year":"2018","journal-title":"Current cardiology reports"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0080","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/pds.4020","article-title":"Statin use and the risk of developing diabetes: a network meta-analysis","volume":"25","author":"Thakker","year":"2016","journal-title":"Pharmacoepidemiology and drug safety"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0081","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.numecd.2017.03.001","article-title":"Statin use and risk of new-onset diabetes: a meta-analysis of observational studies","volume":"27","author":"Casula","year":"2017","journal-title":"Nutrition, metabolism and cardiovascular diseases"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0082","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/eurheartj\/ehy357","article-title":"PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor","volume":"40","author":"Da Dalt","year":"2019","journal-title":"European heart journal"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0083","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2337\/db11-0944","article-title":"miR-33a modulates ABCA1 expression, cholesterol accumulation, and insulin secretion in pancreatic islets","volume":"61","author":"Wijesekara","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0084","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/HCO.0b013e3283470359","article-title":"Are statins diabetogenic?","volume":"26","author":"Sampson","year":"2011","journal-title":"Current opinion in cardiology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0085","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1210\/en.2002-220273","article-title":"Low density lipoprotein can cause death of islet \u03b2-cells by its cellular uptake and oxidative modification","volume":"143","author":"Cnop","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0086","doi-asserted-by":"crossref","first-page":"18368","DOI":"10.1074\/jbc.M300102200","article-title":"Insulin-secreting \u03b2-cell dysfunction induced by human lipoproteins","volume":"278","author":"Roehrich","year":"2003","journal-title":"Journal of biological chemistry"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0087","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1210\/en.2009-0252","article-title":"Low-and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic \u03b2-cells","volume":"150","author":"Rutti","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0088","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0022-2275(20)31566-2","article-title":"ABCA1: the gatekeeper for eliminating excess tissue cholesterol","volume":"42","author":"Oram","year":"2001","journal-title":"Journal of lipid research"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0089","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2337\/dc09-1562","article-title":"Carriers of loss-of-function mutations in ABCA1 display pancreatic \u03b2-cell dysfunction","volume":"33","author":"Vergeer","year":"2010","journal-title":"Diabetes care"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0090","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/MOL.0000000000000521","article-title":"Unexplained reciprocal regulation of diabetes and lipoproteins","volume":"29","author":"Higuchi","year":"2018","journal-title":"Current opinion in lipidology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0091","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jama.2016.14568","article-title":"Association between low-density lipoprotein cholesterol\u2013lowering genetic variants and risk of type 2 diabetes: a meta-analysis","volume":"316","author":"Lotta","year":"2016","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0092","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","article-title":"PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study","volume":"5","author":"Schmidt","year":"2017","journal-title":"The Lancet diabetes & endocrinology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0093","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jama.2015.1206","article-title":"Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus","volume":"313","author":"Besseling","year":"2015","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0094","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.febslet.2009.12.018","article-title":"PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities","volume":"584","author":"Mbikay","year":"2010","journal-title":"FEBS letters"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0095","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bbrc.2009.10.138","article-title":"PCSK9 is expressed in pancreatic \u03b4-cells and does not alter insulin secretion","volume":"390","author":"Langhi","year":"2009","journal-title":"Biochemical and biophysical research communications"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0096","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s00125-015-3659-8","article-title":"The loss-of-function PCSK9 p. R46L genetic variant does not alter glucose homeostasis","volume":"58","author":"Bonnefond","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0098","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2337\/dc17-1464","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes: a systematic review and meta-analysis with over 96,000 patient-years","volume":"41","author":"de Carvalho","year":"2018","journal-title":"Diabetes care"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0099","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/dom.13235","article-title":"Effect of proprotein convertase subtilisin\/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: a systematic review and meta-analysis. Diabetes","volume":"20","author":"Cao","year":"2018","journal-title":"obesity and metabolism"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0100","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/dom.13599","article-title":"PCSK9 inhibitor therapy: a systematic review and meta-analysis of metabolic and cardiovascular outcomes in patients with diabetes","volume":"21","author":"Monami","year":"2019","journal-title":"Diabetes, obesity and metabolism"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0101","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/1074248420924983","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibitors and ezetimibe on risk of new-onset diabetes: a systematic review and meta-analysis of large, double-blinded randomized controlled trials","volume":"25","author":"Chiu","year":"2020","journal-title":"Journal of cardiovascular pharmacology and therapeutics"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0102","first-page":"ehz430","article-title":"Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials","author":"Guedeney","year":"2019","journal-title":"European heart journal"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0103","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jacl.2018.01.004","article-title":"Long-term efficacy and safety of proprotein convertase subtilisin\/kexin 9 monoclonal antibodies: a meta-analysis of 11 randomized controlled trials","volume":"12","author":"Bai","year":"2018","journal-title":"Journal of clinical lipidology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0104","first-page":"1","article-title":"Safety of proprotein convertase subtilisin\/kexin type 9 monoclonal antibodies in regard to diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","author":"Chen","year":"2019","journal-title":"American journal of cardiovascular drugs"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0105","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.amjcard.2017.07.047","article-title":"Effect of the proprotein convertase subtilisin\/kexin type 9 inhibitor evolocumab on glycemia, body weight, and new-onset diabetes mellitus","volume":"120","author":"Sattar","year":"2017","journal-title":"American journal of cardiology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0106","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/eurheartj\/ehy432","article-title":"PCSK9 in diabetes: sweet, bitter or sour?","volume":"40","author":"Paneni","year":"2019","journal-title":"European heart journal"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0107","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S1043-6618(05)80047-7","article-title":"Pharmacology and mechanism of action of the new HMG-CoA reductase inhibitors","volume":"22","author":"Sirtori","year":"1990","journal-title":"Pharmacological research"},{"issue":"5","key":"10.1016\/j.clinthera.2021.12.005_bib0108","article-title":"PCSK9 deficiency modulates glucose homeostasis and insulin secretion via pancreatic LDL receptors and cholesterol accumulation","volume":"9","author":"He","year":"2020","journal-title":"American journal of biomedical science and research"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0109","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.2337\/db07-0056","article-title":"Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic \u03b2-cell dysfunction","volume":"56","author":"Hao","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0110","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1253\/circj.CJ-10-0110","article-title":"Pleiotropic effects of statins\u2014basic research and clinical perspectives","volume":"74","author":"Zhou","year":"2010","journal-title":"Circulation journal"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0111","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs. Silver Spring, MD, USA: Food and Drug Administration [Google Scholar], 2012."},{"key":"10.1016\/j.clinthera.2021.12.005_bib0112","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ejim.2014.03.003","article-title":"Statin therapy and related risk of new-onset type 2 diabetes mellitus","volume":"25","author":"Ruscica","year":"2014","journal-title":"European journal of internal medicine"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0113","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"The Lancet"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0114","first-page":"2018","article-title":"Is atorvastatin associated with new onset diabetes or deterioration of glycemic control? Systematic review using data from 1.9 million patients","author":"Angelidi","year":"2018","journal-title":"International journal of endocrinology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0115","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.jacc.2010.10.047","article-title":"Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials","volume":"57","author":"Waters","year":"2011","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0116","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1007\/s00125-014-3374-x","article-title":"Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis","volume":"57","author":"Erqou","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0117","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15277\/bjd.2018.161","article-title":"Cardiovascular outcomes trials with statins in diabetes","volume":"18","author":"Naeem","year":"2018","journal-title":"British journal of diabetes"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0118","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.atherosclerosis.2019.11.027","article-title":"Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes","volume":"293","author":"Ramin-Mangata","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0119","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.atherosclerosis.2014.07.010","article-title":"PCSK9 levels in abdominally obese men: association with cardiometabolic risk profile and effects of a one-year lifestyle modification program","volume":"236","author":"Arsenault","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0120","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jacc.2016.11.037","article-title":"Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials","volume":"69","author":"Robinson","year":"2017","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0121","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-reduction variability and antidrug-antibody formation with bococizumab","volume":"376","author":"Ridker","year":"2017","journal-title":"New England journal of medicine"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0122","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"The lancet diabetes & endocrinology"},{"key":"10.1016\/j.clinthera.2021.12.005_bib0123","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1093\/eurheartj\/ehw292","article-title":"No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies","volume":"37","author":"Colhoun","year":"2016","journal-title":"European heart journal"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821004987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821004987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:56:22Z","timestamp":1758963382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821004987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":122,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0149291821004987"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.12.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}